

2 Months

Study	Country	Design		VE (95% CI)
Andrews et al. (67) (age 19-49)	UK	TN	H	0.78 (0.76, 0.79)
Andrews et al. (67) (age 50+)	UK	TN	\	0.82 (0.81, 0.83)
Ranzani et al. (38)	Brazil	MTN	H	0.34 (0.33, 0.35)
Gonzalez et al. (80)	Argentina	MTN	 	0.19 (0.17, 0.20)
			0 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)	

3 Months

